KDR and lung adenocarcinoma: In lung adenocarcinoma, the inhibition of EZH2 reduced the malignant potential of lung adenocarcinoma and increased the sensitivity of cells to platinum and vascular endothelial growth factor receptor 2 targeted therapy.95